Literature DB >> 16361259

Nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator, an ABC transporter, catalyze adenylate kinase activity but not ATP hydrolysis.

Christian H Gross1, Norzehan Abdul-Manan, John Fulghum, Judith Lippke, Xun Liu, Prakash Prabhakar, Debra Brennan, Melissa Swope Willis, Carlos Faerman, Patrick Connelly, Scott Raybuck, Jonathan Moore.   

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel in the ATP-binding cassette (ABC) transporter family. CFTR consists of two transmembrane domains, two nucleotide-binding domains (NBD1 and NBD2), and a regulatory domain. Previous biochemical reports suggest NBD1 is a site of stable nucleotide interaction with low ATPase activity, whereas NBD2 is the site of active ATP hydrolysis. It has also been reported that NBD2 additionally possessed adenylate kinase (AK) activity. Knowledge about the intrinsic biochemical activities of the NBDs is essential to understanding the Cl(-) ion gating mechanism. We find that purified mouse NBD1, human NBD1, and human NBD2 function as adenylate kinases but not as ATPases. AK activity is strictly dependent on the addition of the adenosine monophosphate (AMP) substrate. No liberation of [(33)P]phosphate is observed from the gamma-(33)P-labeled ATP substrate in the presence or absence of AMP. AK activity is intrinsic to both human NBDs, as the Walker A box lysine mutations abolish this activity. At low protein concentration, the NBDs display an initial slower nonlinear phase in AK activity, suggesting that the activity results from homodimerization. Interestingly, the G551D gating mutation has an exaggerated nonlinear phase compared with the wild type and may indicate this mutation affects the ability of NBD1 to dimerize. hNBD1 and hNBD2 mixing experiments resulted in an 8-57-fold synergistic enhancement in AK activity suggesting heterodimer formation, which supports a common theme in ABC transporter models. A CFTR gating mechanism model based on adenylate kinase activity is proposed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16361259     DOI: 10.1074/jbc.M511113200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  The ABC protein turned chloride channel whose failure causes cystic fibrosis.

Authors:  David C Gadsby; Paola Vergani; László Csanády
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

2.  A mutation in CFTR modifies the effects of the adenylate kinase inhibitor Ap5A on channel gating.

Authors:  Qian Dong; Christoph O Randak; Michael J Welsh
Journal:  Biophys J       Date:  2008-09-19       Impact factor: 4.033

Review 3.  CFTR (ABCC7) is a hydrolyzable-ligand-gated channel.

Authors:  Andrei A Aleksandrov; Luba A Aleksandrov; John R Riordan
Journal:  Pflugers Arch       Date:  2006-09-26       Impact factor: 3.657

4.  The Walker B motif of the second nucleotide-binding domain (NBD2) of CFTR plays a key role in ATPase activity by the NBD1-NBD2 heterodimer.

Authors:  Fiona L L Stratford; Mohabir Ramjeesingh; Joanne C Cheung; Ling-Jun Huan; Christine E Bear
Journal:  Biochem J       Date:  2007-01-15       Impact factor: 3.857

Review 5.  Role of CFTR's intrinsic adenylate kinase activity in gating of the Cl(-) channel.

Authors:  Christoph O Randak; Michael J Welsh
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

6.  Rad50 adenylate kinase activity regulates DNA tethering by Mre11/Rad50 complexes.

Authors:  Venugopal Bhaskara; Aude Dupré; Bettina Lengsfeld; Ben B Hopkins; Angela Chan; Ji-Hoon Lee; Xiaoming Zhang; Jean Gautier; Virginia Zakian; Tanya T Paull
Journal:  Mol Cell       Date:  2007-03-09       Impact factor: 17.970

7.  ATP and AMP mutually influence their interaction with the ATP-binding cassette (ABC) adenylate kinase cystic fibrosis transmembrane conductance regulator (CFTR) at separate binding sites.

Authors:  Christoph O Randak; Qian Dong; Amanda R Ver Heul; Adrian H Elcock; Michael J Welsh
Journal:  J Biol Chem       Date:  2013-08-06       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.